Sign In
Buy RCKT
$2.92
+0.0300 (+1.04%)
At Close: Jun 03, 2026
Why Is Rocket Pharmaceuticals (RCKT) Stock Up 35% Today?
02:15pm, Wednesday, 13'th Sep 2023
Shares of Rocket Pharmaceuticals (NASDAQ: RCKT ) popped sharply higher on Wednesday, making it one of the top-trending tickers. Yesterday, the biotechnology specialist — which focuses on rare childh
Why Shares of Rocket Pharmaceuticals Are Taking Off on Wednesday
11:56am, Wednesday, 13'th Sep 2023
The company also announced a public stock offering that it said was worth $175 million. The clinical-stage biotech focuses on genetic therapies for rare diseases.
Rocket Pharmaceuticals Stock Jumps Most Since 2020. New Gene Therapy Is Potential 'Value Driver.
10:54am, Wednesday, 13'th Sep 2023
Rocket Pharmaceuticals reaches alignment with the Food and Drug Administration regarding its global Phase 2 trial for a treatment of Danon disease.
Rocket Pharmaceuticals Stock Blasts Off on FDA Buzz
10:52am, Wednesday, 13'th Sep 2023
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock is soaring today, after the biotech name reached an "alignment" with the U.S. Food & Drug Administration (FDA) regarding a mid-stage trial design for its
Rocket Pharmaceuticals stock takes flight on FDA agreement
08:45am, Wednesday, 13'th Sep 2023
Rocket Pharmaceuticals Inc (RCKT) shares surged 32% in pre-market trading on Wednesday after the biotechnology company developing gene therapy announced that it has reached an agreement with the US Fo
Rocket Pharmaceuticals: Thriving Gene Therapy With Multiple Catalysts
12:42am, Thursday, 03'rd Aug 2023
Rocket Pharmaceuticals is developing gene therapies for rare diseases, with positive results and safety profiles from clinical trials. The company's financial performance includes $360 million in cash
3 Small-Cap Stocks You Can't Ignore Now
04:34pm, Monday, 12'th Jun 2023
A small-cap stock is a security whose market capitalization ranges between $250 million and $2 billion. Small-cap stocks are often companies that are relatively small and focused on a niche business.
Rocket (RCKT) Heart Disease Drug Gets Fast Track & Orphan Drug Tag
10:27am, Friday, 09'th Jun 2023
The FDA grants fast track tag and orphan drug designation to Rocket's (RCKT) investigational gene therapy candidate, RP-A601, for cardiac indication. The stock gains 2.3% following the news.
Rocket Pharmaceuticals shares rise on FDA fast-track designation for heart disease treatment
08:25am, Thursday, 08'th Jun 2023
Shares of Rocket Pharmaceuticals RCKT, +0.17% gained 2.3% premarket on Thursday after the late-stage biotech company said the U.S. Food and Drug Administration granted fast-track and orphan-drug desig
Rocket Pharmaceuticals: A Catalyst-Rich Year Ahead
02:34pm, Thursday, 11'th May 2023
Today, we peek back in on Rocket Pharmaceuticals, Inc. for the first time in 2023. The company is seeing some momentum from positive trial developments and new-found enthusiasm from the analyst commun
Rocket Pharmaceuticals: Promising Gene Therapy Play With Discounted Entry Point
12:32pm, Thursday, 16'th Feb 2023
Rocket Pharmaceuticals stock trades at ~$19.5 today - back in December 2021 it had hit highs of >$60. The highs were achieved when Rocket's in vivo gene therapy showed promise treating patients with a
Rocket Pharmaceuticals Has A Lot More Upside
11:09am, Thursday, 16'th Feb 2023
Rocket Pharmaceuticals, Inc. performed beautifully for me in the last half year. They have a number of catalysts in the next few months.
Wall Street Analysts Think Rocket Pharmaceuticals (RCKT) Could Surge 163.35%: Read This Before Placing a Bet
11:17am, Monday, 23'rd Jan 2023
The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 163.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
04:01pm, Tuesday, 03'rd Jan 2023
CRANBURY, N.J.--( BUSINESS WIRE )--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rar
Rocket Pharmaceuticals: 2 Regulatory Filings In 2023 Could Propel It Higher
10:50am, Tuesday, 29'th Nov 2022
A Rocket Pharmaceuticals, Inc. regulatory filing to the FDA of LV RP-L201 for Leukocyte Adhesion Deficiency-I is expected in the 1st half of 2023. A regulatory filing to the FDA of LV RP-L102 for Fanc
